[HTML][HTML] Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19
CS Larsen - International Journal of Infectious Diseases, 2022 - Elsevier
Objectives The oral antiviral drugs nirmatrelvir/ritonavir (NMV/r) and molnupiravir have been
approved for early outpatient treatment of COVID-19 to prevent severe disease. Ritonavir …
approved for early outpatient treatment of COVID-19 to prevent severe disease. Ritonavir …
Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19
CS Larsen - International Journal of Infectious Diseases, 2022 - pure.au.dk
Objectives: The oral antiviral drugs nirmatrelvir/ritonavir (NMV/r) and molnupiravir have been
approved for early outpatient treatment of COVID-19 to prevent severe disease. Ritonavir …
approved for early outpatient treatment of COVID-19 to prevent severe disease. Ritonavir …
Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19.
CS Larsen - 2022 - cabidigitallibrary.org
Objectives" The oral antiviral drugs nirmatrelvir/ritonavir (NMV/r) and molnupiravir have
been approved for early outpatient treatment of COVID-19 to prevent severe disease …
been approved for early outpatient treatment of COVID-19 to prevent severe disease …
Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19.
CS Larsen - International Journal of Infectious Diseases: IJID …, 2022 - europepmc.org
Objectives The oral antiviral drugs nirmatrelvir/ritonavir (NMV/r) and molnupiravir have been
approved for early outpatient treatment of COVID-19 to prevent severe disease. Ritonavir …
approved for early outpatient treatment of COVID-19 to prevent severe disease. Ritonavir …
[HTML][HTML] Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19
CS Larsen - International Journal of Infectious Diseases, 2022 - ncbi.nlm.nih.gov
Objectives The oral antiviral drugs nirmatrelvir/ritonavir (NMV/r) and molnupiravir have been
approved for early outpatient treatment of COVID-19 to prevent severe disease. Ritonavir …
approved for early outpatient treatment of COVID-19 to prevent severe disease. Ritonavir …
Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19
CS Larsen - … journal of infectious diseases: IJID: official …, 2022 - pubmed.ncbi.nlm.nih.gov
Objectives The oral antiviral drugs nirmatrelvir/ritonavir (NMV/r) and molnupiravir have been
approved for early outpatient treatment of COVID-19 to prevent severe disease. Ritonavir …
approved for early outpatient treatment of COVID-19 to prevent severe disease. Ritonavir …
Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19
CS Larsen - International Journal of Infectious Diseases, 2022 - ijidonline.com
Objectives The oral antiviral drugs nirmatrelvir/ritonavir (NMV/r) and molnupiravir have been
approved for early outpatient treatment of COVID-19 to prevent severe disease. Ritonavir …
approved for early outpatient treatment of COVID-19 to prevent severe disease. Ritonavir …
Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19.
CS Larsen - International Journal of Infectious Diseases: IJID …, 2022 - europepmc.org
Objectives The oral antiviral drugs nirmatrelvir/ritonavir (NMV/r) and molnupiravir have been
approved for early outpatient treatment of COVID-19 to prevent severe disease. Ritonavir …
approved for early outpatient treatment of COVID-19 to prevent severe disease. Ritonavir …